Gallium citrate uptake is a marker of breast malignancy: true or false?

Muhammed A. Taher, Shanauk Navalkissoor, Andrew J.W. Hilson, John R. Buscombe
Department of Nuclear Medicine, Royal Free Hospital, London, United Kingdom

[Received 25 I 2007; Accepted 28 II 2007]

Abstract
A 34-year old lady had a 67Gallium citrate scan and demonstrated uptake by both of her breasts — diffuse in the right breast, but focal in the left breast at the “9 o’clock position”. Core biopsy from both breasts showed fibroadenoma and no malignant cells were found. Though uptake of 67Gallium citrate is normally associated with malignancy or infection there may be other causes of uptake and follow-up biopsy should be performed.

Key words: 67Gallium citrate, breast adenoma

Introduction
Gallium is a group III element in the Periodic Table with biological behaviour similar to iron. 67Gallium citrate was developed as a bone-seeking radiopharmaceutical but found use clinically as a tumour-imaging and infection-seeking agent in range of tumours including lymphoma, melanoma, mesothelioma, bronchial carcinoma. Other non-cancerous causes of uptake was found to be infection or inflammation especially in tuberculosis and active sarcoidosis. These infection-seeking property was noted in the early 1970s, and 67Gallium citrate became the mainstay of infection scan for over a decade [1]. 67Gallium binds avidly to the protein lactoferrin and visualization of the breasts of 67Gallium citrate is commonly seen in pre-menopausal woman and is related to normal physiologic stimulation (puberty, postpartum, lactation) of the breast and increase in iron uptake. It has been reported in a small number of patients in the detection of breast cancer [2, 3].

Case report
A 34-year non pregnant, non lactating woman with bilateral hilar lymphadenopathy was seen by a respiratory physician and had a suspected diagnosis sarcoidosis or lymphoma. A confirmatory 67Gallium citrate scan was performed 48 hours after administration of tracer. This demonstrated intense uptake in both breasts — being more diffuse in the right breast, but focal in the left breast at 9 o’clock position (Figure 1). A CT scan of the breast showed that there was high density tissue within both breasts (Figure 2) and subsequent core biopsy from both breasts showed bilateral fibroadenoma with no malignant cells found. There was no evidence for a raised prolactin level.

Discussion
In 1969 Edwards and Hayes noted on a bone scan the accumulation of 67Gallium citrate in the cervical lymphnodes of a pa-
tient with Hodgkin’s disease [4]. Higasi et al [5] used ⁶⁷Gallium citrate scanning in 149 patients with a variety of neoplasms and inflammatory lesions. They found six negative scans among the 16 cases of breast cancer and one false positive case among 19 cases of benign tumour, including six fibroadenomas and 13 cystic tumours — the false positive case was accompanied by inflammation which was thought to be the cause of the uptake of the ⁶⁷Gallium citrate and it was concluded that ⁶⁷Gallium citrate imaging is helpful only in advanced breast cancer or infection but no uptake was seen in benign breast tumours [6]. In hyperprolactinemia, ⁶⁷Gallium citrate localizes in the breasts in a diffuse, bilaterally symmetrical pattern and not normally in the mixed diffuse and focal pattern seen in this patient. Other non-physiological causes for breast uptake of ⁶⁷Gallium citrate include certain medications such as cimetidine, infections including breast abscess, and primary or metastatic malignancies. Indeed it may be necessary to give women who are lactating specific radiation protection advice if the have a ⁶⁷Gallium citrate injection to prevent the child receiving a significant does for injected ⁶⁷Gallium labelled milk.

**Conclusion**

Though it has previously been reported that non-physiological uptake of ⁶⁷Gallium citrate in the breast if there is no endocrine disturbance is due to infection or malignancy it would appear that benign breast disease may also be a cause. Therefore, when unexplained breast uptake of ⁶⁷Gallium citrate is seen biopsy should be performed.

**Acknowledgements**

Dr M.A.Taher was supported be a grant from the International Atomic Energy Agency and the British Council.

**References**